A question has been on my mind for some time: if a pharmaceutical company leads in AI readiness, does that translate into leadership in discovering and commercialising new molecules? The answer — based on analysis of two independent benchmarks across the top 50 life science companies — is more nuanced than most AI investment narratives suggest.
I cross-referenced the CB Insights AI Readiness Index (measuring talent, execution, and innovation) with the IDEA Pharma Innovation & Invention Index 2025 (measuring market impact and pipeline depth). The results are instructive — and in some cases, surprising.
The Correlation — and Its Limits
There is a correlation between AI readiness and molecule innovation success. But it is far from guaranteed. Some of the biggest AI investors in the industry are struggling to translate technology investments into pipeline depth and commercial outcomes. Others, with comparatively modest AI profiles, are outperforming on molecule delivery.
The data points to a fundamental lag effect: there is a 3 to 5 year gap between AI deployment and measurable drug development outcomes. AI investment is forward-looking capability building — and organisations that treat it as a short-term productivity tool will be disappointed.
The Leaders: Alignment in Action
13 AI investments in two years. Consistent pipeline depth and novel molecule discovery. The clearest example of AI capability combining with strong R&D culture to produce commercial outcomes.
AI capability paired with a strong R&D culture has produced consistent pipeline depth. Three consecutive years at the top of the invention index is not a coincidence — it reflects deliberate integration.
The Disconnects: High Investment, Low Translation
The more instructive cases are those where AI readiness and molecule innovation do not align.
| Company | AI Readiness Rank | Innovation / Invention Rank | Assessment |
|---|---|---|---|
| Eli Lilly | #1 | #1 / #1 | Aligned — best in class |
| AstraZeneca | #4 | #1 (3 years) | Aligned — sustained excellence |
| Bayer | #3 | Bottom 10 | High AI, low molecule output |
| Merck KGaA | #2 | #30 / #26 | AI prowess, pipeline weakness |
Bayer ranks third in AI readiness with 21 partnerships — yet sits in the bottom ten of the innovation index. Merck KGaA ranks second in AI readiness and is among the poorest performers in translating molecules through development to market. High AI capability is not yet delivering new molecules.
What the Data Actually Tells Us
- AI readiness does not equal immediate molecule success. The 3–5 year lag between AI deployment and measurable R&D outcomes means that today's investment rankings will not show up in today's pipeline data. AI investment is forward-looking; molecule output is a lagging indicator.
- Integration beats investment. It is not about AI spend — it is about embedding AI into discovery, development, and clinical trial design as a working capability, not a technology initiative. Culture and organisational readiness determine whether investment becomes outcome.
- Pipeline strategy must guide AI strategy. Oncology captures one third of all pharma AI partnerships. Organisations that align their AI investments with their specific therapeutic areas and molecule types outperform those that treat AI as a horizontal platform without scientific direction.
- External collaboration accelerates discovery. Top performers increasingly leverage AI-powered ecosystems combining biotech innovation with pharma scale. The era of building everything in-house is over.
AI readiness without drug development execution excellence is just potential. Molecule innovation leadership without AI investment is increasingly unsustainable. The winners — Eli Lilly and AstraZeneca being the clearest current examples — are the organisations that excel at both. The gap between AI investment and molecule output is not a technology problem. It is an integration problem. And integration is a leadership and organisational challenge, not a technical one.
Sources: CB Insights AI Readiness Index 2025 · IDEA Pharma Global Innovation & Invention Index 2025